US Pharma MarketingRoche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset
Roche is spending $190 million upfront to license a non-incretin obesity drug from South Korea’s Hanmi Pharm. The deal represents the latest in a string of obesity pacts inked by Roche in recent years, including ...
Roche is spending $190 million upfront to license a non-incretin obesity drug from South Korea’s Hanmi Pharm.
The deal represents the latest in a string of obesity pacts inked by Roche in recent years, including ...
Source: Endpoints News